 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | timbetasin topical (RGN-137) / RegeneRx, timbetasin ophthalmic (RGN-259) / ReGenTree
Journal: Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis. (Pubmed Central) - Apr 25, 2023
Our previous work has shown that topical T?4 as an adjunct to ciprofloxacin treatment reduces inflammatory mediators and inflammatory cell infiltrates (neutrophils/PMN and macrophages) while enhancing bacterial killing and wound healing pathway activation in an experimental model ofP...Adjunctive thymosin beta 4 treatment holds novel therapeutic potential to regulate and, optimally, resolve disease pathogenesis in the cornea and perhaps other infectious and immune-based inflammatory disease. We plan to establish the importance of thymosin beta 4 as a therapeutic agent in conjunction with antibiotics with high impact for immediate clinical development.
- | timbetasin topical (RGN-137) / RegeneRx
Preclinical, Journal: Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway. (Pubmed Central) - Mar 2, 2023
In this study, we evaluated an animal model of pulmonary fibrosis complicated with LC by implanting LC cells orthotopically into the lungs of mice several days after bleomycin induction of the pulmonary fibrosis in the same mice...The establishment of the IPF-LC animal model will be helpful for the development of drugs for the treatment of IPF-LC. Exogenous rhT?4 can be potentially used for the treatment of IPF and LC.
- | timbetasin topical (RGN-137) / RegeneRx
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Aug 22, 2022
P2, N=4, Terminated, Sponsor: Lenus Therapeutics, LLC
Exogenous rhT?4 can be potentially used for the treatment of IPF and LC. N=15 --> 4 | Trial completion date: Jun 2022 --> Nov 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2021; Business Decision
- | timbetasin topical (RGN-137) / RegeneRx
Journal: Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in Pseudomonas aeruginosa-Induced Keratitis. (Pubmed Central) - Dec 31, 2021
Collectively, these data provide further evidence that adjunctive Tβ4 + ciprofloxacin treatment offers a more efficacious option for treating bacterial keratitis. Not only does the adjunctive therapy address both the infectious pathogen and corneal wound healing response, but it also influences MΦ infiltration, activation, and function, as revealed by the current study.
- | timbetasin topical (RGN-137) / RegeneRx
Trial completion date, Trial primary completion date: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Sep 21, 2021
P2, N=15, Recruiting, Sponsor: Lenus Therapeutics, LLC
Not only does the adjunctive therapy address both the infectious pathogen and corneal wound healing response, but it also influences MΦ infiltration, activation, and function, as revealed by the current study. Trial completion date: Aug 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
- | timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Mar 6, 2019
P2, N=15, Recruiting, Sponsor: Lenus Therapeutics, LLC
Trial completion date: Aug 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Dec 2021 Initiation date: Nov 2019 --> Mar 2019
- | timbetasin topical (RGN-137) / RegeneRx
Enrollment open: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Nov 14, 2018
P2, N=15, Recruiting, Sponsor: Lenus Therapeutics, LLC
Initiation date: Nov 2019 --> Mar 2019 Not yet recruiting --> Recruiting
- | timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Nov 6, 2018
P2, N=15, Not yet recruiting, Sponsor: Lenus Therapeutics, LLC
Not yet recruiting --> Recruiting Initiation date: Nov 2018 --> Nov 2019
- | timbetasin topical (RGN-137) / RegeneRx
New P2 trial: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Jul 5, 2018
P2, N=15, Not yet recruiting, Sponsor: GtreeBNT Co., Ltd.
- timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 6, 2013
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
Initiation date: Nov 2018 --> Nov 2019 Initiation date: Jan 2005 --> Feb 2006
- timbetasin topical (RGN-137) / RegeneRx
Trial termination: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jan 25, 2012
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
Initiation date: Jan 2005 --> Feb 2006 Completed --> Terminated; Lack of patient availability and expiration of study drug